Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.33 |
| ▸ | BTK | Q06187 | 3/20 | 0.33 |
| ▸ | LPL | P06858 | 4/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA3 | P07451 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12703333 | 0.83 | LPL (0.42) | JAK2BTKLPLLIPGCA1 | |
| SCHEMBL12616496 | 0.74 | LPL (0.36) | JAK2BTKLPLLIPGCA1 | |
| SCHEMBL27611992 | 0.73 | JAK2 (0.35) | JAK2BTKLPLLIPGCA1 | |
| SCHEMBL23167283 | 0.73 | JAK2 (0.40) | JAK2BTKLPLLIPGCA1 | |
| SCHEMBL23166872 | 0.73 | LPL (0.35) | JAK2BTKLPLLIPGCA1 | |
| SCHEMBL11927624 | 0.71 | LPL (0.44) | JAK2BTKLPLLIPGCA1 | |
| SCHEMBL2732956 | 0.71 | LIPG (0.35) | JAK2BTKLPLLIPG | |
| SCHEMBL19610355 | 0.70 | CSF1R (0.36) | JAK2BTKLPLLIPGCA1 | |
| SCHEMBL4426027 | 0.70 | JAK2 (0.32) | JAK2BTKLPLLIPG | |
| SCHEMBL2825036 | 0.70 | F11 (0.36) | JAK2BTKLPLLIPGCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023154282-A1 | COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |